ALPHAMEMORY, LLC

Biotech · Private

Small molecule therapeutics targeting the transmembrane domain of amyloid precursor protein to reduce amyloid production in Alzheimer's disease

Grants
$252K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Phase I STTR: Targeting substrate of gamma-secretase for selective amyloid reduction in Alzheimer’s Disease$252,124
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3357CHRONUS PHARMACEUTICALS, INC.——
3358True North Therapeutics——
3359Neomorph——
3360ALPHAMEMORY, LLC——
3361CORMEDIX, INC.—$3.5M
3362ACTINOBAC BIOMED, INC.—$3.4M
3363Vernal Biosciences, Inc.—$22M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.